醒脑静辅助卡马西平治疗脑卒中后继发性癫痫的临床疗效及安全性评价

Clinical Efficacy and Safety Evaluation of Xingnaojing Injection Assisted Carbamazepine Therapy for Post Stroke Epilepsy

目的探讨醒脑静辅助卡马西平治疗脑卒中后继发性癫痫(PSE)的临床疗效及安全性。方法将2010年12月至2013年12月恩施市中心医院收治的80例继发性癫痫患者按照随机数字表法分为两组,各40例。对照组仅给予卡马西平进行治疗,每次0.1 mg,口服,每日3次;观察组在此基础上给予醒脑静进行治疗,20 m L醒脑静注射液与100 m L葡萄糖溶液进行静脉滴注,每日1次。7 d为1个疗程,连续治疗4个疗程。比较两组患者的临床疗效,治疗前后痫样放电和累及导联数,生活质量及不良反应发生率。结果观察组总有效率为92.5%(37/40),对照组为70.0%(28/40),差异有统计学意义(P<0.05)。治疗后对照组痫样放电与累及导联数分别为(11.2±4.4)t/180 s、(5.4±1.4)/180 s,观察组分别为(6.9±1.3)t/180 s、(3.0±0.6)/180 s,均较治疗前显著降低,且治疗后观察组上述指标均显著小于对照组(P<0.01)。治疗后观察组生活质量评分显著优于对照组(P<0.01);观察组不良反应发生率和对照组分别为10.0%(4/40)和20.0%(8/40),差异无统计学意义(P>0.05)。结论醒脑静辅助卡马西平治疗继发性癫痫疗效显著,安全性高。

Objective To explore the clinical efficacy and safety of Xingnaojing assisted carbamazepine in the treatment of post stroke epilepsy（PSE）. Methods Total of 80 secondary epilepsy patients admitted to Enshi Center Hospital from Dec. 2010 to Dec. 2010 were randomly divided into two groups：control group （40 cases ） receiving carbamazepine treatment （ 0.1 mg/time, oral, 3 times per day ）, observation group （ 40 cases） receiving Xingnaojing（ i. v. 20 mL with 100 mL glucose solution） treatment on the basis of the control group＇ s treatment. The clinical efficacy, epilepsy discharge and involved lead number and quality of life before and after treatment and the incidence of adverse reactions of the two groups were compared. Results The clinical curative effect of the observation group was 92.5% （37/40） ,of the control group was 70.0% （28/40） ,the differences was statistically significant（ P 〈 0.05 ）. After treatment, epileptiform discharge and the number of involved leads of the control group were （ 11.2 ± 4.4 ） t/180 s, （ 5.4 ± 1.4 ）/180 s, of the observation group were （ 6.9 ± 1.3 ） t/180 s, （ 3.0 ± 0.6）/180 s, which were all significantly lower than before treatment, and the observation group＇s data were significantly less than that of the control group after treatment（ P 〈0.01 ）. After treatment, quality of life of the observation group was significantly better than the control group （ P 〈 0. 01 ）. The incidence of adverse reaction of the observation group and control group were 10.0% （4/40） and 20.0% （ 8/40 ）, the difference was not statistically significant （ P 〉 0. 05 ）. Conclusion Xingnaojing assisted carbamazepine treating PSE has obvious therapeutic effect and high safety.